The latest user fee program to finish renewal talks is that for biosimilars. FDA and industry officials confirmed that both sides are in the process of ratifying the resulting commitment letter.
Neither FDA nor industry officials would reveal specific details about the agreement, but it appears BsUFA II will incorporate changes to the application review system along with resource improvements for a program
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?